Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2003

View Archived Issues

Neurocrine Biosciences updates clinical development progress

FDA approves Humatrope for short stature

Positive opinion for new Zyprexa indication in Europe

Botulinum toxin A effective and safe in chronic myofascial pain

Phase II trial indicates promising efficacy for alemtuzumab in MF/SS

Beneficial effects found for EGF enema and oral mesalamine in ulcerative colitis

Additive antitumor effects described for SU-5416 and dalteparin in a glioblastoma cell line

Evidence of antitumor effects of DMXAA in refractory solid tumors

Dendreon completes acquisition of Corvas

Factive receives expanded FDA approval

Abbott and Dharmacon collaborate to develop siRNA library

Immunomodulator MM-093 enters phase I study

EPI-hNE4 designated European orphan drug for cystic fibrosis

Positive phase II results for AC-2592 in CHF

AVX-101 enters clinic

AltaStaph enters phase II in low-birth-weight neonates

Impavido improves cure rate in phase III cutaneous leishmaniasis trial

Enrollment completed in phase II trial of Ceplene in hepatitis C nonresponders

Cangene enters R&D partnership to develop hyperimmunes related to SARS

Human breast cancer growth inhibited by nocturnal melatonin

Bisphosphonates: methods for treatment of bone disorders claimed

Phosphatase inhibitors useful for diabetes claimed by Roche

BMS designs antiinflammatory agents with the ability to protect cartilage

Treatment of CNS disorders using 5-HT1D receptor ligands

Selective oxytocin receptor antagonists and their use reported by Japanese lab

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026